Nano cap biotech Trovagene (TROV) debuts a KRAS genetic test that utilizes a urine sample instead of blood or tissue. The company offers the test as a service (laboratory-developed test). It detects the seven most common mutations in the KRAS oncogene.
Consensus revenue estimates for 2013 and 2014 are $360K and $4.2M, respectively.
24 mutual funds have positions, up from 11 a year ago.